Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAPDH | P04406 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | HRAS | P01112 | 1/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.46 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11655811 | 1.00 | GAPDH (0.56) | GAPDHMEN1USP2POLBKMT2A | |
| SCHEMBL5991719 | 0.90 | MEN1 (0.55) | GAPDHMEN1USP2POLBKMT2A | |
| SCHEMBL5991726 | 0.88 | MEN1 (0.55) | GAPDHMEN1USP2POLBKMT2A | |
| SCHEMBL7143681 | 0.87 | MEN1 (0.56) | GAPDHMEN1USP2POLBKMT2A | |
| SCHEMBL10260643 | 0.83 | MEN1 (0.58) | GAPDHMEN1USP2POLBKMT2A | |
| SCHEMBL15702572 | 0.83 | MEN1 (0.58) | GAPDHMEN1USP2POLBKMT2A | |
| SCHEMBL8394491 | 0.83 | GAPDH (0.47) | GAPDHMEN1USP2POLBKMT2A | |
| SCHEMBL8394489 | 0.83 | GAPDH (0.47) | GAPDHMEN1USP2POLBKMT2A | |
| SCHEMBL13787611 | 0.81 | GAPDH (0.56) | GAPDHMEN1USP2POLBKMT2A | |
| SCHEMBL14428974 | 0.80 | MEN1 (0.52) | GAPDHMEN1USP2POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642206-B2 | Useful in treating a wide variety of diseases including infections, infestations, neoplasms and autoimmune diseases | ICN PHARMACEUTICALS, INC. | 2003-11-04 | — | — | US | disclosed |
| US-6573248-B2 | Therapeutic agent for use in the treatment of tumors, infections, infestation and autoimmune disease | ICN PHARMACEUTICALS, INC. | 2003-06-03 | — | — | US | disclosed |
| US-20020095033-A1 | Monocyclic L-nucleosides, analogs and uses thereof | ICN PHARMACEUTICALS, INC. | 2002-07-18 | — | — | US | disclosed |
| US-6130326-A | Monocyclic L-Nucleosides, analogs and uses thereof | ICN PHARMACEUTICALS, INC. (US) | 2000-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020095033-A1 | Monocyclic L-nucleosides, analogs and uses thereof | PNP, TYMP, SLC29A1 | GAPDH 802/4885MEN1 548/4885USP2 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.